Clinical Trials Logo

Clinical Trial Summary

This is an exploratory cluster randomized controlled trial to evaluate the effect of a kefir beverage, enriched with prebiotics components, on immunity, lipid profile and adiposity in a population-based study, using the family as the intervention unit.


Clinical Trial Description

The gastrointestinal tract is populated by a collection of microorganisms, primarily bacteria, that interact with intestinal host cells. In the past two decades, several studies have demonstrated the effects of the intestinal microbiota on host physiological, metabolic and immunological processes and have revealed that the microbiota is fundamental to host body function. There is currently a growing interest in manipulating the intestinal microbiota to enhance the effects on health and welfare of the intestine. In this regard, since its introduction, the concept of prebiotics has stimulated both scientific and industrial interest. A dietary prebiotic is a selectively fermented ingredient that results in specific changes, in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefits upon host health. To date, the prebiotics most widely evaluated in human clinical trials are inulin-type fructans (inulin, fructo-oligosaccharides, oligofructose) and galacto-oligosaccharides (GOS).

The investigators goal is to conduct a human clinical trial to evaluate the impacts of a functional-prebiotic beverage on immunity and metabolic profile.

This study will be performed on a family-oriented basis. 44 families/clusters (~ 150 children and adults, older than 3 years) will be selected to participate in the study and will be randomized into intervention group (n=22 families) and control (n=22 families) groups.

Weight, body mass index (BMI), waist circumference (WC), nutrient intake from food frequency questionnaire, physical activity, blood pressure, allergic sensitization, metabolic function (fasting blood glucose, HbA1c, insulin resistance and lipid profile), general lymphocyte overview (B-cells, T-cells and NK-cells) and sub-populations of T-helper cells (Th1, Th2, Th17 and T-regulatory), inflammation markers (C-reactive protein, interleukin-6 and tumor necrosis factor-alpha) will be measured at baseline and after 4 months.

Mixed effect models analysis will be performed to assess changes in the cardiometabolic and immune parameters. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03312660
Study type Interventional
Source Hospital Clinico Universitario de Santiago
Contact
Status Completed
Phase N/A
Start date April 10, 2017
Completion date November 27, 2017

See also
  Status Clinical Trial Phase
Completed NCT04043000 - Super 13 Pro & Prebiotics on the Human Intestinal Microflora N/A
Completed NCT01201577 - Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals Phase 1
Completed NCT04706858 - Integrative Personal Omics Profiling for Dynamic Molecular Phenotypes Monitoring During Fiber Supplementation N/A
Completed NCT03336385 - Prebiotic Supplementation and Intestinal Barrier Function in Elderly: a RCT N/A
Recruiting NCT03554694 - Gut-brain Axis, Brain Function, and Behaviour. N/A
Recruiting NCT05821010 - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis Phase 2
Completed NCT01549782 - Mixture of Prebiotics on Intestinal Microbiota of Patients Receiving Abdominal Radiotherapy. N/A
Completed NCT02118402 - Iron and Prebiotics Fortification in Kenyan Infants N/A
Recruiting NCT03925597 - Multiomic Signatures of Microbial Metabolites Following Prebiotic Fiber Supplementation N/A
Completed NCT02679183 - Medically-Graded Honey Supplementation Formula To Preterm Infants Phase 0
Completed NCT05584254 - Effects of β-glucans on Gut Permeability and Microbiota in Elderly N/A